Cardiovascular Nuclear Imaging: Balancing Proven Clinical Value and Potential Radiation Risk

The Cardiovascular Council Board of Directors

The debate on the potential risk of radiation exposure from diagnostic imaging tests highlights the importance of balancing the demonstrated clinical benefit and the theoretic risk of cardiovascular imaging studies. The Cardiovascular Council of the Society of Nuclear Medicine upholds the responsible application of imaging studies that use radiotracers associated with relatively small amounts of ionizing radiation. Radionuclide-based cardiac imaging studies, including myocardial perfusion imaging (MPI), provide accurate and prognostic information about patients with suspected or known heart disease. There is a large body of scientific evidence on the clinical value of MPI, based on studies performed on many thousands of patients. On the basis of this information, appropriate-use criteria and guidelines were developed and endorsed by the Society of Nuclear Medicine and other professional societies, including the American College of Cardiology, American Heart Association, and American Society of Nuclear Cardiology (1).

Cardiovascular nuclear medicine studies provide highly sensitive and specific tests that may be indicated for the evaluation of diagnosis, prognosis, and treatment response of coronary artery disease, as well as for selection of patients who benefit from revascularization. The value and justification of MPI for risk assessment is based on large observational outcome studies that demonstrate accurate risk stratification with radionuclide-based MPI in populations with an intermediate pretest risk. The incremental prognostic value of SPECT MPI is greater than that of the exercise electrocardiography stress test or coronary angiography. The cost effectiveness of MPI as a gatekeeper to coronary angiography has been established after being carefully and extensively studied.

Several recent publications have raised concern about the potential harmful effects of ionizing radiation associated with cardiac imaging. Review of the measurement of radiation and associated biologic effects can help put this issue into reasonable perspective. Radiation effective dose is a measure used to estimate the biologic effects of radiation. Measuring the radiation effective dose associated with diagnostic imaging is complex and imprecise and often results in varying estimates among experts (2). A typical effective dose for a rest–stress same-day SPECT scan using $^{99m}$Tc-labeled agents (1,110 MBq [30 mCi] stress, 370 MBq [10 mCi] rest), the most commonly used MPI protocol, is approximately 10 mSv. Other agents and protocols are associated with a wide range of radiation exposure (2). In comparison, exposure to radiation from natural sources amounts to approximately 3 mSv annually. The risk of a fatal malignancy from medical imaging–related radiation is difficult to estimate precisely but is likely small and difficult to discern from the background risk of natural malignancies. The theoretic lifetime attributable risk of cancer from a rest and stress $^{99m}$Tc-based MPI study for individuals age 35 y or older is less than 1.5 in 1,000 (3). This risk is less in older patients, who constitute most patients evaluated for coronary artery disease. The estimated risk of fatal malignancy from a typical MPI study is 0.5 per 1,000 individuals, compared with a risk of death from natural cancer of 212 per 1,000 (4).

The potential risk of cancer must be balanced against the risk of death, myocardial infarction, or other morbidity and mortality events in an appropriately referred population. This risk ranges from 1% to 10% or more per year and is orders of magnitude greater than the potential lifetime risk of cancer and death from cancer attributable to cardiovascular nuclear medicine studies. Assessment of risk-to-benefit ratio mandates a good understanding of the clinical characteristics of the patient, including risk factors for coronary artery disease, prior history of coronary artery disease, and left ventricular function. For example, given the substantially higher risk of morbid coronary events or heart failure in patients with left ventricular dysfunction, higher radiation exposure associated with $^{201}$Tl or $^{18}$F-FDG for radionuclide assessment of viability is readily justifiable. In this context, one must not fail to take into account the risks of missing important diagnostic information by not performing a test (which could potentially influence near-term management and outcomes) because of a theoretic concern about a long-term small risk of malignancy. Similarly, assessment of the significance of radiation exposure risk in population-based studies would be challenging without information on the overall pool from which the patients are selected and how representative the patients are of the total patient population.

While the potential long-term radiation risk associated with cardiovascular nuclear medicine studies is debated (5),
the Cardiovascular Council supports adherence to the principle of ALARA (as low as reasonably achievable) in the context of performing the appropriate study to address the clinical question effectively. Before performing an MPI study, we must ensure the appropriateness of the study and use a protocol that delivers the least radiation while maintaining diagnostic accuracy and clinical effectiveness. A review of medical records for old studies and a discussion with the referring clinician about the current study may be prudent. The likelihood that the study being considered will affect the clinical management of the patient should be addressed before testing is performed. Routine periodic follow-up scans of asymptomatic individuals should be avoided. We wish to highlight new opportunities for reducing radiation from MPI through development of innovative hardware and software techniques (6), new imaging protocols (e.g., stress-only imaging (7)), and more widespread use of PET (8). These developments may bring the exposure down to less than 5 mSv for complete rest–stress perfusion studies. In parallel, there is a need for novel tracers with improved diagnostic accuracy and reduced radiation exposure and for clinical translation of potentially transformative novel developments in cardiovascular molecular imaging. The usefulness of alternative diagnostic strategies in comparison with SPECT and PET MPI in selecting and monitoring the effectiveness of treatment strategies will need to be addressed.

In summary, radionuclide MPI can provide scientifically validated, accurate, and in certain cases unique information for management of patients with known or suspected coronary artery disease at risk for major cardiovascular events. The radiation exposure risk associated with radionuclide MPI, albeit small and long term as opposed to the higher and more immediate risk for major cardiovascular events, mandates careful adherence to appropriateness criteria and guidelines developed or endorsed by the Society of Nuclear Medicine, American Society of Nuclear Cardiology, American College of Cardiology, and American Heart Association. With recent developments in technology, there are many opportunities to further reduce radiation exposure and further enhance the benefit-to-risk ratio of this well-established, safe imaging modality.

**RECOMMENDATIONS FOR MINIMIZING RADIATION EXPOSURE AND OPTIMIZING THE CLINICAL USE OF RADIONUCLIDE CARDIAC IMAGING**

- Adherence to American College of Cardiology/American Heart Association/American Society of Nuclear Cardiology/Society of Nuclear Medicine appropriate-use criteria for radionuclide imaging is recommended.
- Radionuclide MPI in asymptomatic low-risk or intermediate-risk individuals with an interpretable electrocardiogram should be avoided as a first test.
- Routine use of PET and $^{99m}$Tc-based SPECT MPI studies instead of protocols with higher radiation exposure should be considered.
- Use of nonradioactive, less expensive modalities (e.g., exercise treadmill test) to identify optimal MPI candidates should be considered.
- Incorporation of stress-only protocols is encouraged.
- Implementation of novel software and hardware with the goal of reducing radiation exposure in accordance with the principle of ALARA is encouraged.

**APPENDIX**

The Cardiovascular Council Board of Directors

- **Mehran M. Sadeghi**
  President
  Yale University School of Medicine
  New Haven, Connecticut

- **Ronald G. Schwartz**
  Vice President
  University of Rochester Medical Center
  Rochester, New York

- **Robert S. Beanlands**
  Vice President-Elect
  University of Ottawa Heart Institute
  Ottawa, Canada

- **Mouaz H. Al-Mallah**
  Intern
  Henry Ford Hospital
  Detroit, Michigan

- **Frank M. Bengel**
  Immediate Past-President
  Medizinische Hochschule Hannover
  Hannover, Germany

- **Salvador Borges-Neto**
  Board Member
  Duke University Medical Center
  Durham, North Carolina

- **Elias H. Botvinick**
  Board Member
  University of California–San Francisco
  San Francisco, California

- **Dominique Delbeke**
  Board Member
  Vanderbilt University Medical Center
  Nashville, Tennessee

- **Nancy McDonald Deloatch**
  Board Member
  St. Vincent’s Medical Center
  Jacksonville, Florida

- **Marcelo F. Di Carli**
  Board Member
  Brigham and Women’s Hospital
  Boston, Massachusetts
REFERENCES


Cardiovascular Nuclear Imaging: Balancing Proven Clinical Value and Potential Radiation Risk

Doi: 10.2967/jnumed.111.090654

This article and updated information are available at:
http://jnm.snmjournals.org/content/52/7/1162

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml